0.3% GSK1940029 gel

DRUG2 trials

Sponsors

GlaxoSmithKline

Conditions

Acne Vulgaris

Phase 1

Study to Evaluate the Safety, Tolerability and Pharmacokinetic of Single and 14 Day Repeat Topical Application of GSK1940029

CompletedNCT01938482

GlaxoSmithKlineAcne Vulgaris

Start: 2013-10-31End: 2015-02-17Updated: 2017-05-09

Study to Investigate the Irritation Potential of GSK1940029 Gel

CompletedNCT01984801

GlaxoSmithKlineAcne Vulgaris

Start: 2013-10-14End: 2015-04-10Updated: 2017-05-09